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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYFrontotemporal dementia (FTD) is a frequent form of early-onset dementia and can be caused bymutations inMAPTencoding themicro-
tubule-associated protein TAU. Because of limited availability of neural cells from patients’ brains, the underlying mechanisms of neuro-
degeneration in FTD are poorly understood.Here, we derived induced pluripotent stem cells (iPSCs) from individualswith FTD-associated
MAPTmutations and differentiated them intomature neurons. Patient iPSC-derived neurons demonstrated pronounced TAU pathology
with increased fragmentation and phospho-TAU immunoreactivity, decreased neurite extension, and increased but reversible oxidative
stress response to inhibition of mitochondrial respiration. Furthermore, FTD neurons showed an activation of the unfolded protein
response, and a transcriptome analysis demonstrated distinct, disease-associated gene expression profiles. These findings indicate distinct
neurodegenerative changes in FTD caused by mutant TAU and highlight the unique opportunity to use neurons differentiated from
patient-specific iPSCs to identify potential targets for drug screening purposes and therapeutic intervention.INTRODUCTION
Frontotemporal dementia (FTD) comprises a group of
neurodegenerative diseases and is the second most com-
mon early-onset dementia after Alzheimer’s disease (AD),
having a prevalence of 15–22/100,000 person-years
(Boxer and Miller, 2005; Knopman and Roberts, 2011).
FTD is characterized by cortical degeneration of the frontal
and temporal lobes (frontotemporal lobar degeneration
[FTLD]) leading to impairment of behavior, language,
and cognition (Boxer and Miller, 2005; Goedert et al.,
2012). About 20%–30% of patients have hereditary forms
of FTD, and up to 15%–20% of these patients carry muta-
tions in the MAPT gene located on chromosome 17q21,
which encodes the microtubule-associated protein TAU
(Goedert and Spillantini, 2011). FTD patients with MAPT
mutations present with dementia and Parkinson-like
motor impairment due to additional degeneration of
subcortical brain areas, including the substantia nigra
(SN). Thus, this form of FTD was termed FTD and Parkin-
sonism linked to chromosome 17 (FTDP-17; for review,
see Ghetti et al., 2015).TAU is a neuronal protein that stabilizes microtubules
and axoplasmic transport, establishes neuronal polarity,
mediates axonal outgrowth and dendritic positioning,
and protects DNA from heat damage and oxidative stress
(Noble et al., 2013). Six different TAU isoforms are ex-
pressed in the adult human brain as a result of alternative
splicing of exons 2, 3, and 10 (Goedert et al., 1989). While
exons 2 and 3 encode for amino-terminal TAU domains,
exon 10 encodes for one of the four microtubule-binding
domains in the carboxy-terminal half of TAU (Goedert
et al., 1989). In the normal brain, the ratio of isoforms
including exon 10 (4R isoforms) to those isoforms devoid
of exon 10 (3R isoforms) is usually balanced, but in some
FTDP-17 patients, this ratio is shifted toward 4R isoforms,
leading to increased deposition of 4R TAU protein within
neurons and glial cells (Goedert and Spillantini, 2011).
A pathological hallmark of FTDP-17 is the deposition of
excessive amounts of hyperphosphorylated TAU (p-TAU)
protein in neurons and glial cells in affected brain areas,
including neural cells within the temporal cortex and
dopaminergic (DA) neurons of the SN. Hyperphosphoryla-
tion of TAU is thought to suppress its ability to stabilizeStem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors 83
microtubules, resulting in axonal degeneration and even-
tual cell death (for review, see Noble et al., 2013). Deposi-
tion of p-TAU is not limited to FTD caused by mutant
MAPT but is seen in about 40%–45% of all FTD patients,
grouped together with FTDP-17 as FTLD-TAU, and includes
patients with Pick’s disease, progressive supranuclear palsy
(PSP), and corticobasal degeneration (Goedert et al., 2012;
Irwin et al., 2015). Furthermore, excessive accumulation
of p-TAU is found in patients with AD, which together
with FTLD-TAU forms the large group of neurodegenera-
tive tauopathies.
Despite thorough characterization of histopathological
hallmarks in FTDP-17, mechanisms leading to neuronal
degeneration remain largely elusive. This originates, at
least in part, from the limited availability of viable neurons
from patients’ brains. In this context, induced pluripotent
stem cells (iPSCs) uniquely enable the identification of
mechanisms of disease development in patient-derived
neurons. As such, iPSCs have been widely used to study
neurodegenerative changes in a variety of neurodegenera-
tive disorders such as Parkinson’s disease (PD), AD,
or FTD caused by mutant GRN or mutant C9ORF72
(Almeida et al., 2012, 2013; Cooper et al., 2012; Hargus
et al., 2010; Reinhardt et al., 2013b; Soldner et al., 2009;
for review, see Hargus et al., 2014b). Here, we generated
iPSCs from individuals with MAPT mutations as an
in vitro model of FTDP-17 to identify distinct neurodegen-
erative changes in FTDP-17.RESULTS
Derivation and Characterization of iPSCs
We derived iPSCs from individuals carrying the N279K
MAPT mutation (referred to as FTDP-17-1) or the V337M
MAPT mutation (referred to as FTDP-17-2), located in
exons 10 and 12, respectively. iPSCs were generated by
lentiviral transduction of fibroblasts with a polycistronic
vector encoding OCT4, KLF4, SOX2, and C-MYC. The
same procedure was applied to derive iPSCs from two
healthy individuals (Ctrl-1 and Ctrl-2). An additional
control iPSC line was also included in this study (Ctrl-3),
which had been generatedwith the same four transcription
factors (Reinhardt et al., 2013b). Altogether, four FTDP-17
iPSC clones (FTDP-17-1-I, FTDP-17-1-II, FTDP-17-2-I, and
FTDP-17-2-II) and four Ctrl-iPSC clones (Ctrl-1-I, Ctrl-1-II,
Ctrl-2-I, and Ctrl-3-I) were used in this study. Undifferenti-
ated iPSCs expressed the pluripotency-associated markers
OCT4, NANOG, SSEA-4, TRA 1-60, and TRA 1-81 (Fig-
ure 1A) and expressed OCT4, KLF4, SOX2, and C-MYC
at levels comparable to those in H9 embryonic stem
cells (ESCs) (Figure 1B). Sanger sequencing confirmed the
N279K and the V337M MAPT mutation in FTDP-17-84 Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authorspatient-derived stem cells (Figures 1C and 1D). Further-
more, we performed whole-genome microarray analysis
on undifferentiated Ctrl- and FTDP-17 iPSCs (Figure 1E).
This analysis revealed comparable expression profiles
in all iPSC clones, which were similar to those of ESCs,
but clearly differed from those of fibroblasts (Figure 1E).
FTDP-17 and Ctrl cells carried normal karyotypes
(Figure 1F), and teratoma formation assays confirmed
pluripotency of iPSCs, which differentiated into meso-
dermal, endodermal, and ectodermal derivatives in vivo
(Figure 1G).
Neuronal Differentiation Is Not Impaired
in FTDP-17 iPSCs
We have recently developed a protocol to efficiently
generate neural progenitor cells and mature neurons from
human pluripotent stem cells (Hargus et al., 2014a; Rein-
hardt et al., 2013a). Using this protocol, we observed effi-
cient derivation of NESTIN+ and SOX1+ neural progenitor
cells from both Ctrl- and FTDP-17 iPSCs (Figure 2A). Pro-
genitor cells from both groups subsequently differentiated
at similar efficiencies into mature bIII-TUBULIN+ neurons
(Figure 2B). Approximately 45% of these neurons were
g-aminobutyric acid+ GABAergic neurons (Figures S1A
and S1B), and about 50% were midbrain-like FOXA2+ and
tyrosine hydroxylase+ (TH+) DA neurons, which are at sig-
nificant risk in FTDP-17 (Figures 2B–2E; Slowinski et al.,
2007); 2%–4% of all neurons were choline acetyltransfer-
ase+ cholinergic neurons (Figures S1C and S1D). To further
characterize maturation of iPSC-derived neurons, we
obtained electrophysiological recordings using the patch-
clamp technique. Both Ctrl- and FTDP-17 neurons fired
evoked action potentials with no obvious differences in
size, shape, and amplitude (Figure 2F). Furthermore, whole
cell voltage-clamp currents and tetrodotoxin (TTX) sensi-
tivity of action potentials indicated functional voltage-
gated Na+ channel inward currents in both Ctrl and
FTDP-17 iPSC-derived neurons (Figure 2F). These data
demonstrated proper maturation of iPSC-derived neurons
in vitro and indicated that neuronal differentiation is not
impaired in FTDP-17 iPSCs.
Altered Expression of TAU in FTDP-17 iPSC-Derived
Neurons
As mutantMAPT causes FTDP-17, we next set out to inves-
tigate whether FTDP-17 neurons exhibit altered expression
of TAU on mRNA and protein levels. Thus, we first
performed qPCR analysis for total TAU and for different
TAU isoforms in differentiated Ctrl and FTDP-17 iPSCs
(Figures 3A–3C and S2A). An analysis of total TAU expres-
sion revealed varying expression levels among the different
iPSC clones but no significant differences between the Ctrl
and FTDP-17 group (Figure 3A). Similarly, expression levels
Figure 1. Derivation and Characterization of Ctrl and FTDP-17 iPSCs
(A) Immunostainings of FTDP-17-1 and FTDP-17-2 iPSCs demonstrating expression of pluripotency-associated markers. Scale bars
represent 400 mm.
(B) qRT-PCR expression analysis of endogenous OCT4, SOX2, KLF4, and C-MYC in iPSC clones and H9 ESCs. Data are represented as mean of
three replicates +SEM.
(C and D) DNA sequencing electropherograms from genomic DNA of differentiated Ctrl-1-I, Ctrl-2-I, FTDP-17-I-1, and FTDP-17-2-I iPSCs
confirming the presence of the heterozygous N279K MAPT mutation in exon 10 in FTDP-17-1 cells and the heterozygous V337M MAPT
mutation in exon 12 in FTDP-17-2 cells.
(E) Heatmap demonstrating whole-genome expression profiles of human fibroblasts (Fib), of undifferentiated Ctrl and FTDP-17 iPSCs, and
of H1 and H9 ESCs.
(F) G-banded karyotype analysis of differentiated Ctrl and FTDP-17 iPSCs.
(G) H&E stainings of teratoma showing differentiation of FTDP-17-1 and FTDP-17-2 iPSCs into mesoderm, endoderm, and ectoderm in vivo.
The scale bar represents 200 mm.of TAU isoforms, including exon 2, did not differ between
Ctrl and FTDP-17 neurons (Figure 3B). Isoforms containing
exon 3 were not detected in any of the cultures. However,
we observed mutation-specific differences in the expres-
sion of 4R TAU isoforms, which include exon 10 (Figures
3C, 3D, and S2A). FTDP-17-1-I/II neurons carrying the
N279K mutation expressed significantly higher levels of
4R TAU, in contrast to FTDP-17-2-I/II neurons carrying
the V337M mutation, which showed 4R TAU expression
levels comparable to Ctrl neurons. This observation
was important for the validation of our iPSC model ofFTDP-17 since in brains of FTDP-17 patients, some MAPT
mutations, including the N279K mutation, lead to
missplicing of MAPT with an increased expression of 4R
TAU, while others, including the V337M mutation, do
not (Goedert and Spillantini, 2011).
Next, we investigated the expression of TAU protein in
Ctrl and FTDP-17 neurons by western blotting (Figures
3E–3K). By using the HT7 TAU antibody, we observed
a band of around 52 kDA in both Ctrl- and FTDP-17 neu-
rons, reflecting predominant expression of fetal TAU, as
previously described for in vitro-differentiated humanStem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors 85
Figure 2. Differentiation of Ctrl and FTDP-17 iPSCs into Mature Neurons
(A) Immunostainings for SOX1 (red) and NESTIN (green) demonstrating differentiation of Ctrl and FTDP-17 iPSCs into neural progenitor
cells. Nuclei were counterstained with DAPI (blue). The scale bar represents 50 mm.
(B and C) Immunostainings for (B) TUJ1 (bIII-TUBULIN, red) and TH (green) as well as (C) for FOXA2 (red) and TH (green) showing
differentiation of Ctrl and FTDP-17 iPSCs into mature midbrain-like DA neurons. Nuclei were counterstained with DAPI (blue). Scale bars
represent 50 mm in (B) and 10 mm in (C).
(D and E) Quantification of immunostainings for (D) bIII-TUBULIN and (E) TH. Data are represented as mean of replicates from three
independent differentiation experiments +SEM.
(F) Representative traces of evoked action potentials during current-clamp recordings of Ctrl and FTDP-17 neurons with inserts depicting
single action potentials at30 mV (n = 7; left). Whole-cell voltage-clamp currents (n = 7; middle) and TTX sensitivity of action potentials
(n = 5; right) indicate functional voltage-gated Na+ channel inward currents. The indicated scales apply to the complete panel.
All recordings were performed on cells from one differentiation experiment per line.
See also Figure S1.ESC-derived neurons (Iovino et al., 2010). Furthermore,
we identified TAU fragments with a size of 25–27 kDa,
which were only weakly expressed in Ctrl neurons but
strongly expressed in FTDP-17 neurons (Figure 3E).
Thus, it is possible that the N279K and the V337M
MAPT mutations result in increased fragmentation of
full-length TAU protein, as previously described for the
A152T MAPT variant in differentiated neurons (Fong
et al., 2013). To address this possibility, we quantified
full-length TAU and fragments in Ctrl and FTDP-17 neu-86 Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authorsrons and found increased amounts of TAU fragments in
FTDP-17-1-I/II and FTDP-17-2-I/II neurons at the expense
of full-length TAU (Figures 3F and 3G). These findings
of increased TAU fragmentation were reproduced using
three different TAU antibodies directed against the central
core (TAU-5; Figures 3H and 3I), the C terminus (TAU-
C17; Figures S2B and S2C), and the N terminus of TAU
(TAU-A12; Figures S2D and S2E) as well as with an anti-
body that specifically recognizes CASPASE-cleaved TAU
(TAU-C3; Figures 3J and 3K).
Next, we performed immunostainings on Ctrl and FTDP-
17 neurons using the AT8 antibody, which detects p-TAU
(Figures 3L–3O). In comparison to Ctrl cultures, we
observed significantly increased numbers of AT8+/TH+ neu-
rons in FTDP-17-1-I/II cultures (Figures 3L and 3M) and
significantly increased numbers of AT8+/MAP-2+ neurons
in FTDP-17-1-I/II and also FTDP-17-2-I/II cultures (Figures
3N and 3O). These findings are consistent with widespread
expression of AT8+ p-TAU within the brains of FTDP-17
patients and mutation-specific deposition of AT8+ p-TAU
in midbrain DA neurons of patients (Slowinski et al.,
2007). In both Ctrl and FTDP-17 neurons, p-TAU showed
a punctate expression pattern and was mainly localized
to the axonal compartment with some additional perinu-
clear staining. An intracellular aggregation of p-TAU or a
pathologic somatodendritic redistribution of p-TAU was
not observed in our cells, as similarly seen in a previous
study on iPSC-derived neurons carrying the A152T variant
of MAPT (Fong et al., 2013).
Neurite Extension Is Impaired in FTDP-17
iPSC-Derived Neurons
Next, we wondered whether the pronounced TAU pathol-
ogy in FTDP-17 neurons influenced microtubule function,
as TAU is a microtubule-associated protein. Neurites from
FTDP-17 neurons appeared much shorter and at smaller
densities than neurites from Ctrl neurons. Thus, a neurite
outgrowth assay, quantifying neurite length of bIII-
TUBULIN+ neurons 24 and 48 hr after plating, was per-
formed to identify any impairment of neurite extension
(Figures 4A–4C). Already 24 hr after plating, the length of
FTDP-17-1-I/II and FTDP-17-2-I/II neurons was mildly,
but significantly, shorter than those of Ctrl neurons (Fig-
ure 4B). By 48 hr, Ctrl neurons had almost doubled their
neurite extensions, while FTDP-17 neurons presented
with similar neurite lengths as seen at 24 hr after plating
(Figure 4B). Only FTDP-17-2-I/II neurons showed a mild
but significant increase in neurite length between 24 and
48 hr after seeding (Figure 4B). We performed the same
analysis on TH+ DA Ctrl and FTDP-17 neurons, which
revealed similar results (Figure 4C). These observations
indicated impaired neurite morphology and complexity
in FTDP-17-iPSC-derived neurons.
Increased Oxidative Stress and Activation of the
Unfolded Protein Response in FTDP-17 Neurons
FTDP-17 patients show pronounced and widespread
neurodegeneration as a result of increased cellular vulnera-
bility. Thus, we next investigated whether FTDP-17
neurons are more susceptible to oxidative stress. We
measured responses of Ctrl and FTDP-17 neurons to
rotenone, which induces oxidative stress by inhibiting
complex I of the mitochondrial respiratory chain (Figures4D–4G). This experiment revealed increased vulnerability
of FTDP-17 neurons toward respiratory stress, as measured
by enhanced lactate dehydrogenase (LDH) release 48 hr
after application of either 100 or 200 nM rotenone (Fig-
ure 4D). Concomitantly, an increased number of cleaved-
CASPASE-3+ neurons was detected in cultures of FTDP-17
neurons (Figure 4E). Notably, cell death in stressed FTDP-
17 neurons significantly declined after application of the
antioxidant coenzyme Q10 (0.5 and 1 mM) or the GSK-3
inhibitor CHIR99021 (0.5 and 1 mM; Figures 4F and 4G).
These findings indicated that FTDP-17 neurons are more
susceptible to oxidative stress and that reversal of oxidative
stress is possible in FTDP-17 neurons.
In a variety of neurodegenerative diseases, misfolded
proteins accumulate within the ER and activate an ER stress
response, which eventually results in apoptosis (Schro¨der
and Kaufman, 2005). Thus, we further investigated
whether ER stress is involved in the pathogenesis of
FTDP-17. ER stress response is known as the unfolded pro-
tein response (UPR) and involves an altered expression of
themolecular chaperone binding immunoglobulin protein
(BiP), which binds to the protein kinase RNA-like ER kinase
(PERK) under unstressed conditions. Upon initiation of ER
stress, BiP dissociates fromPERK, leading to increased levels
of activated phosphorylated PERK (p-PERK) with increased
expression of pro-apoptotic proteins such as p53-upregu-
lated modulator of apoptosis (PUMA; Tan et al., 2014). To
investigate UPR activation in FTDP-17, we determined
expression levels of BiP, p-PERK, and PUMA in FTDP-17
and Ctrl neurons by western blot analysis (Figures 4H and
4I). We found significantly increased levels of BiP, p-PERK,
and PUMA in FTDP-17 neurons when compared with Ctrl
neurons (Figures 4H and 4I). These findings indicated sig-
nificant UPR activation in FTDP-17 neurons and pointed
toward increased ER stress in FTDP-17.
Altered Gene Expression Profiles in FDTP-17
iPSC-Derived Neurons
We next performed whole-genome transcriptome analysis
bymicroarrays onCtrl- and FTDP-17 neurons to investigate
whether gene expression profiles were altered in FTDP-17
neurons (Figure 5). As expected, expression profiles of
both Ctrl- and FTDP-17 neurons differed significantly
from undifferentiated iPSCs and formed a separate cluster
in the hierarchical cluster analysis reflecting efficient
neuronal maturation (Figures 5A and 5B). We investigated
genes that were significantly upregulated or downregulated
in FTDP-17-1 and FTDP-17-2 neurons in comparison to
Ctrl cells (p values % 0.01; Figures 5C–5F, S3A, and S3B;
Table S1). This analysis revealed similar, overlapping
gene expression profiles in FTDP-17-1 and FTDP-17-2
neurons with 59 upregulated genes in FTDP-17-1 and 42
upregulated genes in FTDP-17-2 neurons (Figure 5C).Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors 87
Figure 3. TAU Pathology in FTDP-17 iPSC-Derived Neurons
(A–C) qRT-PCR on Ctrl and FTDP-17 iPSC-derived neurons for (A) total TAU, for (B) TAU isoforms containing exon 2, and for (C) 4R TAU
isoforms containing exon 10. Expression levels were normalized to Ctrl-1-I/II and GAPDH as housekeeping gene. Data are represented as
mean of replicates from three independent experiments per indicated lines (n = 6) +SEM. One-way-ANOVA with post hoc Tukey test was
performed for statistical analysis (***p < 0.001).
(D) Electrophoretic separation of 3R and 4R TAU isoforms.
(legend continued on next page)
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Similarly, compared with Ctrl neurons, 130 and 113 genes
were downregulated in FTDP-17-1 and FTDP-17-2 neurons,
respectively (Figure 5D). Functional annotation of
these downregulated genes was associated with Gene
Ontology (GO) terms such as altered monooxygenase
activity (CYP46A1, TH), altered GTPase regulator activity
(ARHGDIB, BCR, THY1, RAPGEF4), and disturbed cytoskel-
eton organization and biogenesis (ADRA2A, AMOT,
ARHGDIB, THY1, RND1; Table S1). Downregulated genes
also included PAK3, a kinase associated with cytoskeletal
reorganization and mental retardation (Allen et al., 1998),
and RIT2, a RAS family GTPase and a susceptibility factor
for PDwith decreased expression in the SNof patients (Pan-
kratz et al., 2012). Furthermore, we observed significantly
decreased expression of SERP2 (stress-associated ER protein
family member 2) and VGF, which have been linked to ER
and ER-associated stress (Figure 5E; Shimazawa et al., 2010).
Functional annotation of upregulated genes was related
to GO terms such as cell-cycle arrest (INHA) and cellular
biosynthesis process (AK5, APOA1, INHA, RPSY4Y1, DMD;
Table S1). Interestingly, particularly highly expressed
genes in FTDP-17 neurons included LOC100128252
(ZNF667-AS1), a non-coding RNA transcript with currently
unknown function, andMAGEH1, an intracellular protein,
which interacts with the p75 receptor, a neurotrophin
receptor with context-dependent functions promoting
either cellular integrity or cellular death to neural cells
(Figure 5F; Casaccia-Bonnefil et al., 1999; Tcherpakov
et al., 2002).
To investigate a potential role of MAGEH1 in the patho-
genesis of FTDP-17, we examined the effects of aMAGEH1
gene knockdown in FTDP-17 neurons using a lentiviral
shRNA expression system. We achieved MAGEH1 knock-
down efficiencies of up to 80% compared with scrambled
(scr)-shRNA-expressing FTDP-17 neurons (Figure 5G). We
observed an increased susceptibility of FTDP-17 neurons
with MAGEH1 knockdown (FTDP-17-1/2-I/IIMAGEH1-KD)
to rotenone-induced oxidative stress, as evidenced by an(E–I) Representative western blot analysis on Ctrl and FTDP-17 neurons
with the b-ACTIN antibody as loading control. Independent replicate
TAU protein fragments (G) in Ctrl and FTDP-17 neurons using the HT7 a
ratios of TAU-fragments to full-length TAU (H) in Ctrl and FTDP-17 n
(J and K) Representative western blot on CASPASE-cleaved TAU (J) an
TAU (K) in Ctrl and FTDP-17 neurons.
(F–K) Blot quantifications are represented as mean of replicates from
(n = 12 in F–H; n = 9 in K) +SEM. Student’s t test was performed for
(L and M) Immunostainings of neurons for AT8 (red), TH (green), an
(N and O) Immunostainings of neurons for AT8 (red), MAP2 (green),
(L–O) Data in (M) and (O) are represented as means of replicates fro
ANOVA with post hoc Tukey test was performed for statistical analysi
represent 50 mm.
See also Figure S2.increasednumber of cleaved-CASPASE-3 and bIII-TUBULIN
double+ neurons compared with cultures of scr-shRNA
expressing FTDP-17-1/2 neurons (FTDP-17-1/2-I/IIscr; Fig-
ure 5H). Concomitantly, FTDP-17-1/2-I/IIMAGEH1-KD neu-
rons showed reduced neurite outgrowth compared with
FTDP-17-1/2-I/IIscr neurons supporting a protective effect
of MAGEH1 in FTDP-17 neurons (Figures 5I and 5J). We
also found that knockdown of MAGEH1 in FTDP-17-1/2
neurons was followed by reduced expression of RIT2 and
PAK3, which were already downregulated in FTDP-17-1/2
neurons comparedwithhealthyCtrl cells before the lentivi-
ral treatment (Figures 5E and 5K).
To further elucidate the role ofMAGEH1 in differentiated
neurons, we overexpressed MAGEH1 in healthy control
cells derived from Ctrl-1/2/3 iPSCs (Figures S3C–S3E).
While we did not find any changes in neurite outgrowth af-
ter MAGEH1 overexpression, we observed a significant
decrease in the number of cleaved-CASPASE-3+ neurons
in rotenone-treated MAGEH1 overexpressing Ctrl cultures
(Ctrl-1/2/3-I/IIMAGEH1) when compared with rotenone-
treated healthy Ctrl cultures expressing red fluorescent
protein (RFP; Ctrl-1/2/3-I/IIRFP). These data further sup-
ported a putative neuroprotective effect of MAGEH1 in
mature neurons.
SomePathological Changes AreObserved in theBrains
of FTDP-17 Patients
Next, we investigated whether pathological changes in
FTDP-17 iPSC-derived neurons were also observed in
post-mortem brain tissue of FTDP-17 patients (Figures
6A–6H). We collected midbrain tissue from four patients
carrying either the N279K mutation or the P301L muta-
tion, another frequent, FTDP-17-causing mutation located
in exon 10 ofMAPT. Consistent with our findings in vitro,
we foundmarked expression of AT8+ p-TAU in DA neurons
of the SN and also in non-DAneurons in surrounding brain
stem nuclei (Figures 6A and 6B). In contrast to FTDP-17
neurons in vitro, AT8+ p-TAUwas deposited as cytoplasmic,for TAU protein using the HT7 (E–G) and TAU-5 (H and I) antibodies
s are shown for each line. Quantification of full-length TAU (F) and
ntibody. Analysis of TAU-5 western blots showing quantification of
eurons.
d quantification of CASPASE-cleaved TAU normalized to full-length
three independent differentiation experiments per indicated lines
statistical analysis (*p < 0.05, **p < 0.01, ***p < 0.001).
d DAPI (blue) (L) with quantification (M).
and DAPI (blue) (N) with quantification (O).
m three independent differentiation experiments +SEM. One-way-
s (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bars in (L) and (N)
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Figure 4. Decreased Neurite Outgrowth, Enhanced Vulnerability to Oxidative Stress, and Activation of the UPR in FTDP-17 Neurons
(A) Immunostainings of Ctrl and FTDP-17 neurons for TH (green) and TUJ1 (red) 48 hr after plating. Nuclei were stained with DAPI.
(B and C) Quantification of neurite outgrowth in (B) bIII-TUBULIN+ neurons and in (C) TH+ DA neurons 24 hr and 48 hr after plating.
Neurite outgrowth was assessed by measurement of the longest neurite of each neuron. Data are represented as mean of at least
100 measurements per indicated lines from three independent experiments +SEM. Two-way ANOVA with post hoc Tukey test was used as
statistical test (*p < 0.05, **p < 0.01, ***p < 0.001; ###p < 0.001: denotes effect over time within groups).
(D) Effect of oxidative stress on FTDP-17 and Ctrl neurons analyzed by measurement of LDH release after 48 hr of rotenone treatment.
(E) Quantification of cleaved-CASPASE-3+ DA neurons in Ctrl and FTDP-17 cultures after 48 hr of rotenone treatment.
(F and G) Rescue of FTDP-17 neurons through treatment with (F) CoQ10 or (G) the GSK-3 inhibitor CHIR99021.
(D–G) Data are represented as mean of replicates from three independent experiments +SEM. One-way ANOVA with post hoc Tukey test was
used as statistical test (*p < 0.05, **p < 0.01, ***p < 0.001).
(H) Western blot analyses of ER stress-associated markers PUMA, p-PERK, and BiP in Ctrl and FTDP-17 neurons. GAPDH or b-ACTIN was used
as a loading control.
(I) Quantifications of protein expression in FTDP-17 neurons relative to expression in Ctrl neurons and to expression of GAPDH or b-ACTIN,
respectively. Data are represented as mean of replicates from three independent differentiation experiments per indicated lines
(n = 12) +SEM. Student’s t test was used as statistical test (*p < 0.05; ***p < 0.001).
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Figure 5. Gene Expression Profiles in FTDP-17 and Ctrl Neurons
Whole-genome transcriptome microarray analysis of Ctrl and FTDP-17 neurons derived from three independent differentiations.
(A and B) Whole genome expression profiles presented as (A) heatmap and (B) hierarchical clustering dendrogram.
(C and D) Venn diagram showing the overlap of genes significantly upregulated (C) or downregulated (D) in FTDP-17-1 and FTDP-17-2
neurons.
(E and F) Validation of differentially downregulated (E) and upregulated (F) genes by qRT-PCR. Data are represented as mean of replicates
from three independent experiments per indicated lines +SEM. One-way ANOVA with post hoc Tukey test was used as statistical test
(*p < 0.05, **p < 0.01, ***p < 0.001).
(G) Relative gene expression of MAGEH1 in FTDP-17-1/2-I/IIMAGEH1-KD or FTDP-17-1/2-I/IIscr control neurons.
(H) Quantification of cleaved-CASPASE-3+ neurons in FTDP-17-1/2-I/IIMAGEH1-KD or FTDP-17-1/2-I/IIscr control neurons after 48 hr of
rotenone treatment. At least 800 cells were counted per cell line and differentiation.
(I) Immunostainings of FTDP-17-1/2-I/IIMAGEH1-KD or FTDP-17-1/2-I/IIscr control neurons for bIII-TUBULIN 48 hr after plating as single
cells. Nuclei were stained with DAPI.
(J) Quantification of neurite outgrowth in cultures of FTDP-17-1/2-I/IIMAGEH1-KD or FTDP-17-1/2-I/IIscr control neurons 48 hr after
plating. At least 100 neurons were measured per cell line and differentiation.
(K) Relative expression of the indicated genes in FTDP-17-1/2-I/IIMAGEH1-KD or FTDP-17-1/2-I/IIscr control neurons.
(H, J, and K) Data are presented as mean of independent replicates from four different lines +SEM. Student’s t test was performed for
statistical analysis (*p < 0.05, **p < 0.01).
See also Figure S3 and Table S1.perinuclear aggregates within neurons and as neurofibril-
lary tangles (NFTs) within axonal projections, which ap-
peared morphologically disturbed (Figures 6A and 6B).
AT8+ deposits were also identified in glial cells (Figure 6A).
An analysis of AT8 distribution within the temporal cortexof FTDP-17 patients revealed similar results (Figure 6A).
These changes were accompanied by significant neuronal
cell loss.
The expression of 4R TAU was increased in the patient’s
brains (Figure 6C), and in line with our in vitroStem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors 91
Figure 6. Identification of Pathological Changes in Post-mortem Tissue from FTDP-17 Patients
(A and B) Immunostaining for AT8 demonstrating pronounced p-TAU expression in neurons and glial cells in the midbrain (patients A–C)
and temporal cortex (patient D) of FTDP-17 patients carrying the P301L MAPT mutation (patients A and B) or the N279K MAPT mutation
(patients C and D). The scale bar represents 200 mm. Higher magnification image in (B) reveals AT8 immunoreactivity in FTDP-17 midbrain
neurons with neuropil threads. The scale bar represents 20 mm.
(C) qRT-PCR for detection of 4R TAU isoforms in Ctrl individual and FTDP-17 patient midbrain samples.
(D) Immunostaining for the ER stress marker BiP in the midbrain (patients A–C) and temporal cortex (patient D) of FTDP-17 patients. The
scale bar represents 200 mm.
(E) Western blot analysis of BiP expression in the midbrain of Ctrl individuals and FTDP-17 patients. GAPDH expression was used as loading
control.
(F) Quantification of BiP expression in FTDP-17 patients relative to Ctrl A and normalized to GAPDH expression.
(G and H) qRT-PCR for detection of (G) LOC100128252 and (H) MAGEH1 in Ctrl individual and FTDP-17 patient midbrain samples.
(C, G, and H) Data were normalized to GAPDH expression and to Ctrl A and are represented as mean of triplicates from the same tissue
preparation.observations of increased UPR activation in FTDP-17 neu-
rons, we found abundant expression of BiP protein within
DA and non-DA neurons in histological specimen from
all four FTDP-17 patients (Figure 6D). Since BiP is expressed
to certain extents also under normal conditions, we quan-
tified expression levels by western blot analysis and
processed native, fresh-frozen midbrain tissue from two
FTDP-17 patients and from two Ctrl individuals for molec-
ular analyses.We observed increased levels of BiP protein in
samples from FTDP-17 patients as similarly seen in in vitro-
differentiated FTDP-17 iPSCs (Figures 6E and 6F).
Likewise, we found that some of the aforementioned
dysregulated genes in FTDP-17 iPSC-derived neurons
were also dysregulated in post-mortem tissue from FTDP-
17 patients. Indeed, while PAK3, RIT2, SERP2, and VGF
were not downregulated in post-mortem tissue of FTDP-92 Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors17 patients, we observed that LOC100128252 and
MAGEH1, which were particularly strongly expressed in
FTDP-17 neurons, were also more strongly expressed in
post-mortem tissue of FTDP-17 patients compared with
Ctrl individuals (Figures 6G and 6H). These data further
indicated that these two molecules with currently un-
known function in the context of neurodegeneration
could play a significant role during FTDP-17 pathogenesis.DISCUSSION
We used iPSC-derived neurons to identify distinct
neurodegenerative changes in FTDP-17. We found that
overall neuronal differentiation was not impaired in
FTDP-17 iPSCs. However, FTDP-17 neurons presented
withdisturbedneuritemorphology aswell aswith impaired
neurite extension and exhibited distinct TAU pathology
with increased fragmentation of full-length TAU protein
and an increased immunoreactivity for AT8. FTDP-17
neurons displayed increased and reversible vulnerability
toward oxidative stress and presented with activated
UPR. Furthermore, we have identified genes, which were
significantly dysregulated in FTDP-17 neurons, including
an upregulation of LOC100128252 andMAGEH1. Notably,
some of these pathologic changes could also be identified
in post-mortem material from patients with FTDP-17.
FTDP-17 is caused by MAPT mutations, which lead to
either increased expression of 4R TAU isoforms or to
decreased interaction of TAU protein with microtubules
(Goedert and Spillantini, 2011). As such, we reasoned to
examine FTDP-17 iPSCs, which have been derived from
individuals carrying MAPT mutations representing the
former and the latter group, respectively. Only FTDP-17-1
neurons carrying the N279K mutation expressed increased
amounts of 4R TAU transcripts, while FTDP-17-2 neurons
carrying the V337M mutation showed normal 4R TAU
expression levels, thus reflecting observations made
in vivo. Despite these differences in 4R TAU expression,
most of the observed FTDP-17 disease phenotypes were
almost identical and appeared to similar extents in FTDP-
17-1 and FTDP-17-2 neurons. The major mutation-specific
difference comprised an increased expression of AT8+
p-TAU in FTDP-17-1 neurons, but not in FTDP-17-2 DA
neurons. In contrast, non-DA neurons from both FTDP-
17 patients presented with significantly increased AT8
positivity as compared with the Ctrl groups. These findings
are in line with observations made in vivo, as deposition
of AT8+ p-TAU is especially observed in SN DA neurons of
patients carrying the N279K mutation. On the other
hand, excessive and widespread AT8 positivity is found
in non-DA neurons in brains of patients with the N279K
mutation and in patients with the V337M mutation.
Thus, findings in vivo were mimicked in vitro validating
our iPSC-based model of FTDP-17.
Both the N279K and the V337M mutation render the
TAU protein more susceptible to hyperphosphorylation
(Alonso Adel et al., 2004). When tau becomes hyperphos-
phorylated, it detaches frommicrotubules and destabilizes
microtubule assemblies, thereby affecting microtubule
function (Noble et al., 2013). These findings could explain
the impairment of neurite outgrowth in FTDP-17 neurons.
Furthermore, we found an increased fragmentation of TAU
protein in FTDP-17 neurons at the expense of full-length
TAU, which most likely further contributed to disturbed
neurite morphology. Increased TAU fragmentation and
abnormal neurite morphologies were previously described
in iPSC-derived neurons carrying the A152T variant of
MAPT, which may increase the risk for the developmentof FTD, PSP, and AD (Fong et al., 2013). In this study,
heterozygous A152T neurons showed a similar increase
in TAU fragmentation as compared with gene-corrected
control cells. This effect could further be potentiated by
the introduction of a second mutation at the same site.
Thus, these data support our observation that genetic
changes in MAPT can have significant effects on the struc-
tural integrity of TAU. Fragmentation of TAU can occur
through cleavage by several caspases including caspase-3
(Fasulo et al., 2000). We observed that increased TAU
fragmentation in FTDP-17 neurons was at least in part
mediated by CASPASE-driven proteolysis, as evidenced by
the detection of a truncated TAU protein, which is recog-
nized at its C terminus by a CASPASE-cleaved TAU-specific
antibody. This CASPASE-associated fragmentation was
not specific to the N279K and V337M mutation but also
occurred to a similar extent in neurons carrying the
A152T MAPT variant (Fong et al., 2013). Interestingly,
however, our N279K and V337Mmutant FTDP-17 neurons
expressed an additional low-molecular-weight variant
of CASPASE-cleaved TAU, indicating that a fraction
of CASPASE-cleaved TAU was further truncated at its
N terminus by additional proteases. These data encourage
performing additional comparative studies on iPSC-
derived neurons from patients with different MAPT muta-
tions to better characterize mutation-specific expression
profiles of proteases in FTDP-17.
TAU fragments carry an apoptosis-inducing activity,
which is further potentiated when cells are exposed to
TAU fragments carrying the N279K mutation (Fasulo
et al., 2005). In addition, overexpression of full-length
TAU carrying the N279K or the V337M mutation resulted
in induction of apoptosis after serum deprivation (Furu-
kawa et al., 2000). These findings are consistent with our
data demonstrating an increased vulnerability of FTDP-17
neurons toward oxidative stress induced by the mito-
chondrial complex I inhibitor rotenone. This response
was accompanied by an increased expression of cleaved-
CASPASE-3. Rotenone-induced cytotoxicity has been
observed in an iPSC-based model of PD (Reinhardt et al.,
2013b), which is characterized by an increased vulnera-
bility of midbrain DA neurons as similarly seen in FTDP-
17. Increased cell death of FTDP-17 neurons could, at least
in part and in addition to increased TAU fragmentation,
be related to a direct impact of the N279K and V337M
mutations on mitochondrial function. Such an effect
was recently described for P301L mutant TAU, which
when overexpressed in a neuroblastoma cell line led to
reduced mitochondrial complex I activity and to an
increased vulnerability toward H2O2-mediated oxidative
stress (Schulz et al., 2012).
Stress responses were reversible, as the antioxidant coen-
zyme Q10 prevented cell death in challenged FTDP-17Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authors 93
neurons. Furthermore, GSK-3 inhibition in FTDP-17 neu-
ronsbyCHIR99021 resulted inoverall rescueof cell viability,
consistent with a pro-apoptotic function of GSK-3 in the
context of oxidative stress, as shown in SH-SY5Y cells
(King and Jope, 2005). Furthermore, GSK-3-b showed
increased activity in SH-SY5Y cells upon UPR activation
(Song et al., 2002), which was readily observed in our
FTDP-17 iPSC-derivedneurons.These experimentsprovided
proof of principle that an intervention is possible to prevent
cell death in patients’ neurons at risk. At the same time, they
highlight the unique potential of iPSCs to identify poten-
tially beneficial compounds in FTDP-17, as human neurons
can be produced efficiently and at high numbers for high-
throughput drug screening purposes (Heilker et al., 2014).
While UPR is initially a protective response mechanism
toward misfolded proteins, its prolonged activation can
lead to the onset of apoptosis and eventually to cell death.
We observed an upregulation of BiP protein in FTDP-17
neurons, which was accompanied by an increased ex-
pression of p-PERK and the apoptosis-inducing protein
PUMA. These findings indicated increased ER stress as a
contributing factor to FTDP-17. In line with this observa-
tion, we also found UPR activation in the brains of patients
with FTDP-17. UPR activation has been described in brains
of patients with AD and in cases of FTDL-TAU (Hoozemans
et al., 2009; Nijholt et al., 2012). In neurons of AD patients,
markers of UPR activation appeared at early stages of dis-
ease development and were co-expressed with AT8 prior
to NFT formation (Hoozemans et al., 2009). Furthermore,
a recent whole-genome association study for PSP identified
a small nuclear polymorphism in EIF2AK3, the gene encod-
ing PERK, as a risk factor for the development of PSP (Ho¨g-
linger et al., 2011). These studies and our present data on
FTDP-17 neurons thus demonstrate that TAU pathology
is closely linked to ER stress in tauopathies. The mecha-
nisms, however, by which TAU interferes with ER function
andUPR are still unclear, as TAU is located in the cytoplasm
and not in the ER (Abisambra et al., 2013).
Our whole-genome expression analysis identified dysre-
gulated genes in FTDP-17 neurons. Downregulated genes
included PAK3 and RIT2, which have been linked to
mental retardation (Allen et al., 1998) and PD (Pankratz
et al., 2012), respectively. Upregulated genes included
LOC100128252 (ZNF667-AS1), a non-coding RNA tran-
script with currently unknown function, and the intracel-
lular molecule MAGEH1, both of which were also highly
expressed in the post-mortem brains of FTDP-17 patients.
While further studies have to be performed to characterize
the function of LOC100128252 in the context of FTDP-17,
we could identify a beneficial role of MAGEH1 in patient-
derived neurons. Our MAGEH1 knockdown experiments
revealed increased susceptibility of FTDP-17 neurons to
oxidative stress and demonstrated reduced neurite94 Stem Cell Reports j Vol. 5 j 83–96 j July 14, 2015 j ª2015 The Authorsoutgrowth. Accordingly, overexpression of MAGEH1 in
healthy control neurons resulted in reduced vulnerability
toward oxidative stress, suggesting that upregulation of
MAGEH1 in FTDP-17 neurons represents a so far unknown
endogenous neuroprotective mechanism. MAGEH1 can
associate with the intracellular domain of the p75 receptor
(Tcherpakov et al., 2002), which has been linked to cell
survival and differentiation in neural progenitor cells
(Casaccia-Bonnefil et al., 1999). It remains to be shown
whether the beneficial effects of MAGEH1 in FTDP-17
neurons involve the p75 receptor and further studies are
necessary to identify the mechanisms by which MAGEH1
promotes neuroprotection in FTDP-17 neurons.
In conclusion, our iPSC-based model of FTDP-17 is well
suited for identifying pathways involved in neurodegener-
ative processes in FTDP-17 as it captures a large variety of
disease-specific phenotypes and offers the possibility to
analyze disease-affected cells in vitro. At the same time, it
provides the unique opportunity to use these cells as a plat-
form for drug screening purposes to establish therapeutic
approaches in FTDP-17.EXPERIMENTAL PROCEDURES
Derivation of iPSCs
Fibroblasts from individuals with MAPT mutations, here referred
to as FTDP-17 patients, were obtained from the Coriell Institute
for Medical Research and were reprogrammed using a lentiviral
SF-OSKM-tomato expression vector. See the Supplemental Experi-
mental Procedures for further details, which also includes a list
of antibodies used in this study (Table S2) and a list of the primers
employed for qRT-PCR analyses (Table S3). The work with human
ESCs has been approved by the Robert Koch Institute (Az. 1710-79-
1-4-55-E1).Neurite Outgrowth Assays
After 22 days of terminal differentiation, neurons were singularized
by treatmentwith accutase (PAA) for approximately10minat 37C.
Cells were subsequently diluted in DMEM (PAA) and spun down at
2003 g for 5min. The cell pelletwas resuspended inneuronalmatu-
ration medium, and cells were plated on matrigel-coated 48-well
plates at a density of 3 3 104 cells per well. At 24 and 48 hr after
plating, cells were fixed in 4% paraformaldehyde (Electron Micro-
scopy Sciences) for 20 min at 4C, and neurons were stained for
bIII-TUBULIN and TH. Neurite outgrowth was analyzed in a
double-blinded manner on random fluorescence images and on at
least 100 neurons per iPSC clone using the Image J software.Stress-Induced Cell Death and Rescue
Neuronswere replated after 10 days of neuronal differentiation at a
density of 8 3 103 cells per well into 96-well plates. After another
11 days inmaturationmedium, 100 and 200 nM rotenone (Sigma)
in N2 medium consisting of DMEM-F12 with 1:100 N2 supple-
ment and 1% penicillin/streptomycin/glutamine were added to
the cells for 24 hr. Viability was assessed bymeasuring LDH leakage
in the supernatant using the Cytotoxicity Detection Kit Plus
(Roche). Absorbance was recorded at 490 nm and was expressed
as the percentage of absorbance in control cells after subtraction
of background absorbance. For rescue experiments, 0.5 and 1 mM
CHIR99021 (Axon Medchem) was added to the medium 48 hr
before and throughout rotenone treatment, and 0.5 and 1 mM
Coenzyme Q10 (Sigma) was added to the medium 20 min before
measurement.
Statistics
Data of at least three independent differentiation experiments are
presented as mean + SEM. Statistical significance was determined
by Student’s t test and with one-way ANOVA and two-way
ANOVA with post hoc Tukey test, respectively.
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